• Prescribing Information
  • Medical Information
  • Patient Site
  • Order Prevnar 20TM
  • Sign InAccountSign out
    Sign In
    Sign out

    Broad pneumococcal defense1

    Prevnar 20TM helps protect against the 20 Streptococcus pneumoniae serotypes in the vaccine1

    A next generation of adult pneumococcal protection in one dose1
    Prevnar 20 contains the broadest serotype coverage from a conjugate vaccine against pneumococcal pneumonia1
    Prevnar 20 helps protect against the 20 Streptococcus pneumoniae serotypes in the vaccine1
    Discover broad conjugate coverage
    Recommended by the CDC
    The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends Prevnar 20 as an option for your eligible adult patients.2
    See the detailed guidelines
    Meet Prevnar 20 patient types
    Patient profiles to help you determine which of your adult patients are eligible to receive Prevnar 20.
    ​​​​​​​

    See the patient profiles
    Built on an established vaccine
    Prevnar 20 was built on the efficacy of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]).1,3
    Review the data

    Recommended by the CDC
    ​​​​​​​

    ​​​​​​​The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends Prevnar 20 as an option for your eligible adult patients.2
    ​​​​​​​


     
    See the detailed guidelines

    Meet Prevnar 20 patient types
    ​​​​​​​

    Patient profiles to help you determine which of your adult patients are eligible to receive Prevnar 20.
    ​​​​​​​

    See the patient profiles

    Built on an established vaccine
    ​​​​​​​

    Prevnar 20 was built on the efficacy of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]).1,3
    ​​​​​​​

    Review the data
    References: 1. Prevnar 20™ (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information, Wyeth Pharmaceuticals LLC, 2021. 2. Kobayashi M. Considerations for age-based and risk-based use of PCV15 and PCV20 among U.S. adults and proposed policy options. Presented at: Advisory Committee on Immunization Practices; October 20, 2021. Accessed October 20, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/02-Pneumococcal-Kobayashi-508.pdf 3. Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) Prescribing Information, Wyeth Pharmaceuticals LLC, 2019.

    This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

    ​​​​​Manufactured by Wyeth Pharmaceuticals LLC.
    © 2022 Pfizer Inc.

    ​​​​​​​​​​​​All rights reserved.

     
    Marketed by Pfizer Inc.
    January 2022

     

    ​​​​​Manufactured by Wyeth Pharmaceuticals LLC.
    Marketed by Pfizer Inc.
    © 2021 Pfizer Inc. ​​​​​All rights reserved. November 2021

    • Severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 20™, Prevnar 13®, or to diphtheria toxoid is a contraindication
    • Safety and immunogenicity data on Prevnar 20™ are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20™
    • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response to Prevnar 13®
    • For Prevnar 20™, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in adults 18 through 59 years of age 
    • For Prevnar 13®, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>5%) were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash 

    Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

    ​​​​​​​Please click for Prevnar 20™ Full Prescribing Information.

    Please click for Prevnar 13® Full Prescribing Information.


    • Prevnar 20™ (Pneumococcal 20-valent Conjugate Vaccine) is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older 
    • ​​​​​​​The indication of Prevnar 20™ for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial 
       
    • Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older

       Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine

    INDICATIONS AND SELECT SAFETY INFORMATION

    INDICATIONS

    • Prevnar 20™ (Pneumococcal 20-valent Conjugate Vaccine) is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older
    • The indication of Prevnar 20™ for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial​​​​​​​
    • Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older

       Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine

    SELECT SAFETY INFORMATION

    • Severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 20™, Prevnar 13®, or to diphtheria toxoid is a contraindication
    • Safety and immunogenicity data on Prevnar 20™ are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20™